Free Trial

MorphoSys (MOR) Competitors

MorphoSys logo
$18.96 0.00 (0.00%)
As of 09/19/2025

MOR vs. QGEN, BBIO, ROIV, ELAN, MRNA, VRNA, RVMD, RGC, GRFS, and RYTM

Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Qiagen (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

MorphoSys vs. Its Competitors

Qiagen (NYSE:QGEN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, Qiagen had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Qiagen and 0 mentions for MorphoSys. Qiagen's average media sentiment score of 1.05 beat MorphoSys' score of 0.00 indicating that Qiagen is being referred to more favorably in the media.

Company Overall Sentiment
Qiagen Positive
MorphoSys Neutral

Qiagen has a net margin of 18.30% compared to MorphoSys' net margin of -226.79%. Qiagen's return on equity of 14.77% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen18.30% 14.77% 8.87%
MorphoSys -226.79%-694.31%-22.55%

Qiagen currently has a consensus price target of $49.69, suggesting a potential upside of 8.68%. Given Qiagen's stronger consensus rating and higher possible upside, analysts plainly believe Qiagen is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.27
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Qiagen has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$2.04B4.98$83.59M$1.6927.05
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Qiagen beats MorphoSys on 14 of the 16 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MOR vs. The Competition

MetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.86B$867.03M$5.79B$10.48B
Dividend YieldN/A4.84%5.61%4.57%
P/E Ratio-5.451.20348.9026.87
Price / Sales11.9925.98521.26164.59
Price / CashN/A17.6526.0131.15
Price / Book54.176.4915.546.51
Net Income-$205.35M-$3.95M$3.29B$271.42M
7 Day PerformanceN/A0.89%200.91%3.70%
1 Month PerformanceN/A6.86%184.43%8.10%
1 Year PerformanceN/A21.51%325.57%29.74%

MorphoSys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
QGEN
Qiagen
4.4329 of 5 stars
$45.39
+0.2%
$49.69
+9.5%
+5.3%$10.07B$2.04B26.825,765Positive News
BBIO
BridgeBio Pharma
4.3844 of 5 stars
$51.47
+0.5%
$63.94
+24.2%
+95.8%$9.79B$235.81M-12.58400
ROIV
Roivant Sciences
3.4333 of 5 stars
$13.95
-0.9%
$17.67
+26.6%
+25.6%$9.61B$29.05M-19.93860Positive News
Analyst Revision
ELAN
Elanco Animal Health
2.793 of 5 stars
$18.63
+0.5%
$17.33
-6.9%
+36.3%$9.21B$4.48B21.669,000
MRNA
Moderna
4.4639 of 5 stars
$23.88
+1.6%
$41.81
+75.1%
-61.6%$9.15B$3.06B-3.175,800
VRNA
Verona Pharma PLC American Depositary Share
2.0527 of 5 stars
$106.37
-0.1%
$109.00
+2.5%
+253.5%$8.71B$221.67M-107.4430Positive News
RVMD
Revolution Medicines
4.2654 of 5 stars
$46.20
-0.8%
$73.67
+59.5%
-4.1%$8.70BN/A-10.27250
RGC
Regencell Bioscience
0.1407 of 5 stars
$14.35
-2.4%
N/AN/A$7.27BN/A0.0010
GRFS
Grifols
3.9711 of 5 stars
$9.63
-2.5%
$10.30
+7.0%
+8.8%$6.79B$7.81B8.2323,822Positive News
RYTM
Rhythm Pharmaceuticals
3.102 of 5 stars
$96.03
-0.2%
$101.57
+5.8%
+81.9%$6.39B$156.29M-31.90140Positive News

Related Companies and Tools


This page (NASDAQ:MOR) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners